Fate shares dip after first look at NK cell durability, CAR-NK cell efficacy

Durability concerns about Fate’s first-generation NK cell therapy overshadowed some of the first clinical efficacy data for the biotech’s CAR-NK cell platform — designed to address that very concern — as the company shed nearly $1.8 billion in market cap on Friday. 

Fate Therapeutics Inc. (NASDAQ:FATE) fell $18.62 (22%) to $67.01 after announcing updated data late Thursday for its first two induced pluripotent stem cell (iPS cell)-derived NK cell programs, FT516 and FT596. ...